Maze Therapeutics, Inc. (MAZE) Stock Analysis
A live, multi-source view of Maze Therapeutics, Inc. (MAZE): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Maze Therapeutics, Inc.
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Sector: Healthcare · Industry: Biotechnology · United States · 141 employees · mazetx.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Maze Therapeutics, Inc. (MAZE) had a market capitalization of $1.46B (forward -8.3); the shares traded in a 52-week range of $14.75 – $53.65 (75.1% over the year).
- Market cap
- $1.46B
- Enterprise value
- $1.11B
- Forward P/E
- -8.3
- Price / book
- 3.21
- EPS (trailing)
- $-2.44
- EPS (forward)
- $-3.18
- Payout ratio
- 0.0%
- 52-week range
- $14.75 – $53.65
- 52-week change
- 75.1%
- Average volume
- 547,358
- Shares outstanding
- 55.5M
- Short % of float
- 12.14%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-08
In RapidTradeView’s 2026-09-08 scan of the US universe, Maze Therapeutics, Inc. (MAZE) last closed at $26.21 (the last completed close before that scan).
Technicals at the scan: RSI 40 (neutral territory), price -6.3% versus its 20-day average, 20-day versus 50-day average spread -2.3%, MACD histogram -0.34.
Sentiment inputs: StockTwits 100% bullish; analyst consensus score 77/100.
Next scheduled company event: in 58 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of MAZE; corporate insiders filed 0 buys and 7 sells (3 distinct filers, latest disclosure 2026-08-14). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Jason Coloma V (0B/4S), Atul Dandekar (0B/2S), Harold Bernstein (0B/1S). Who is trading what
RapidTradeView pick record
MAZE has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Maze Therapeutics, Inc. (MAZE) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell MAZE.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.